5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer;Carcinome epidermoide metastatique de l'anus: Etude retrospective de l'efficacite de l'association de 5-fluoro-uracile en perfusion continue et de cisplatine

Bulletin du Cancer

Volumn 86, Issue 10, 1999, Pages 861-865

  Faivre, Corinne ^a   Rougier, Philippe ^a,b   Ducreux, Michel ^a   Mitry, Emmanuel ^a   Lusinchi, Antoine ^c   Lasser, Philippe ^a   Elias, Dominique ^a   Eschwege, François ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c NONE

Author keywords

5 fluorouracil; Anal cancer; Cisplatinum; Metastasis; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ANUS CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; SQUAMOUS CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANUS TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FOLLOW UP; KIDNEY; LIVER RESECTION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE;

ACTUARIAL ANALYSIS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0032760074     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. 1. Cancer incidence in five continents. Vol. V, Lyon : IARC, 1987 : 88.
2. 2. Boman BM, Moertel CG, O'Connel MJ, Scott M, Weiland LH, Beart RW, et al. Carcinoma of the anal canal : a clinical and pathologic study of 188 cases. Cancer 1984 ; 54 : 114-25.
3. 3. Frost DB, Richards PC, Montague ED, Giacoco GG, Martin RG. Epidermoid cancer of the anorecrum. Cancer 1984 ; 53 : 1285-93.
4. 4. Wade DS, Herrera L, Castillo NB, Petrelli NJ. Metastasis to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surg Gynecol Obst 1989 ; 169 : 238-42.
5. 5. Eschwege F, Lasser P, Chavy A, Wibault P, Kac J, Rougier P, Bognel C. Squamous cell carcinoma of the anal canal : treatment by external beam irradiation. Radiother Oncol 1985 ; 3 : 145-50.
6. 6. Papillon J, Montbaron JF. Epidermoid carcinoma of the anal canal : a serie of 276 cases. Dis Colon Rectum 1987 ; 30 : 324-33.
7. 7. Schlienger M, Krzisch C, Pene F, Marin JL, Gindrey-Vie B, Maubans S, et al. Epidermoid carcinoma of the anal canal : treatment, results and prognostic variables in a serie of 242 cases. Int J Radiat Oncol Biol Phys 1989 ; 17 : 1141-51.
8. 8. Tanum G. Treatment of relapsing anal carcinoma. Acta Oncologica 1993 ; 32 : 33-5.
9. 9. Epidermoid anal cancer : results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5 fluorouracil and mitomycin. UKCCCR Anal Cancer Trial Working Party. Lancet 1996 ; 348 : 1049-54.
10. 10. Khehn PG, Beckett R, Eisenberg H, Reed J. Hematogenous metastasis from epidermoid carcinoma of the anal canal. Am J Surg 1965 ; 109 : 445-9.
11. 11. Ajani J, Carrascoch V, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989 ; 87 : 221-4.
12. 12. Wilking N, Petrelli N, Herrera L, Milleman A. Phase II study of combination bleomycin, vincristine and high dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 1985 ; 15 : 300-2.
13. 13. Carey RW. Regression of pulmonary metastases from cloacogenic carcinoma after cisplatinum, 5-fluorouracil treatment. J Clin Gastroenterol 1984 ; 6 : 257-9.
14. 14. Nigro N. An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum 1984 ; 27 : 763-6.
15. 15. Barrelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer : results of a phase III randomised trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997 ; 15 : 2040-9.
16. 16. Herskovic A, Martz K, Al Sarraf M. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl J Med 1992 ; 326 : 1593-8.
17. 17. Department of Veterans Affairs Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991 ; 324 : 1685-90.
18. 18. Gerard JP, Romestaing P, Mahe MA, et al. Cancer du canal anal : rôle de l'association 5-fluoro-uracile et cisplatine. Lyon Chir 1991 ; 87 : 74-6.
19. 19. Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus : results in 35 consecutive patients. J Clin Oncol 1996 ; 14 : 3121-5.
20. 20. Peiffert D, Seitz JF, Rougier P, Francois E, Cvitkovic F, Mirabel X, et al. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer : a French cooperative study. Ann Oncol 1997 ; 8 : 575-81.
21. 21. Brunet R, Bécouarn Y, Pigneux J, Ravaud A, Faivre J, Jeandoz V. Cisplatine et fluoro-uracile en chimiothérapic néoadjuvante des carcinomes épidermoïdes du canal anal. Lyon Chir 1991 ; 87 : 77-8.
22. 22. François E, Sadek H, Vignoud J, Brunet R, Mahjoubi M, Bécouarn Y, Namer M, Rougier P. Cancers épidermoïdes du canal anal (ECA) : activité du cisplatine (P) et 5-fluorouracile (5FU) en perfusion continue (PC) dans les formes métastatiques (M) et/ou récidivanr es localement (RL). Bull Cancer 1991 ; 19 : 571.